Cargando…
Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
BACKGROUND: Significant advances in the pharmacologic treatment of erectile dysfunction (ERD) have occurred in recent years, most notably the introduction of sildenafil, the first oral selective phosphodiesterase type 5 (PDE5) inhibitor, in 1998. Sildenafil quickly gained acceptance by the medical c...
Autor principal: | Campbell, Helen Eloise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438094/ https://www.ncbi.nlm.nih.gov/pubmed/15766322 http://dx.doi.org/10.18553/jmcp.2005.11.2.151 |
Ejemplares similares
-
Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005) -
Effect of Patient Notification of Formulary Change on Formulary Adherence
por: Delate, Thomas, et al.
Publicado: (2005) -
Clinical Monograph: Hormone Replacement Therapy
por: Deady, Joan
Publicado: (2004) -
Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010) -
The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)